Physician profile
Faruk H Orge
NPI 1235310087
$158,404.63
in general payments reported to CMS, 2019-2025
10 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,296 · 2020: $6,358 · 2021: $82.31 · 2022: $174 · 2023: $118K · 2024: $24K · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $118K · Honoraria: $18K · Travel and Lodging: $6,801 · Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $117,597.00 |
| Honoraria | $18,360.00 |
| Travel and Lodging | $6,800.74 |
| Food and Beverage | $736.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $122,008.24 | 2022-2024 | Eylea Hd, Eylea |
| Recordati_rare_diseases_inc. | $21,315.75 | 2022-2025 | Cystadrops |
| Leadiant Biosciences, INC. | $14,636.52 | 2019-2021 | |
| Alcon Vision LLC | $144.91 | 2025 | Unity |
| Amgen INC. | $124.99 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $68.89 | 2021-2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $45.70 | 2019 | |
| Dompe US, INC. | $31.86 | 2024 | Oxervate |
| Eusa Pharma (US) LLC | $17.26 | 2022 | |
| Travere Therapeutics, INC. | $10.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faruk Orge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.